Research programme: non-nucleoside reverse transcriptase inhibitors - Boehringer Ingelheim
Latest Information Update: 24 Sep 2012
At a glance
- Originator Boehringer Ingelheim (Canada)
- Class Pyridines; Quinolines
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 18 Sep 2012 Discontinued - Preclinical for HIV infections in Canada (unspecified route)
- 30 Mar 2005 Data presented at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the pharmacokinetics section
- 13 Sep 2004 Data presented at the 228th American Chemical Society National Meeting - (228th-ACS-2004) have been added to the pharmacokinetics section